The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 52 , ISSUE 4 ( October-December, 2010 ) > List of Articles

EDITORIAL

LABAs and Asthma: From the SMART Study to the SMART Approach

Zarir Farokh Udwadia, Lancelot Mark Pinto

Citation Information : Udwadia ZF, Pinto LM. LABAs and Asthma: From the SMART Study to the SMART Approach. Indian J Chest Dis Allied Sci 2010; 52 (4):191-193.

DOI: 10.5005/ijcdas-52-4-191

License: NA

Published Online: 10-12-2010

Copyright Statement:  NA


Abstract

PDF Share
  1. Walters EH, Walters JA, Gibson MD. Inhaled long acting beta agonists for stable chronic asthma. Cochrane Database Syst Rev: CD001385;2003.
  2. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2009.
  3. Stolley PD. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972;105:883-90.
  4. Crane J, Pearce N, Burgess C, Beasley R. Fenoterol and asthma death. N Z Med J 1989;102:356-7.
  5. Kemp JP, Bierman CW, Cocchetto DM. Dose-response study of inhaled salmeterol in asthmatic patients with 24- hour spirometry and Holter monitoring. Ann Allergy 1993;70:316-22.
  6. Ringdal N, Derom E, Wahlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via turbuhaler. Respir Med 1998;92:1017-21.
  7. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7.
  8. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26.
  9. Haney S, Hancox RJ. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial. Respir Res 2005;6:107.
  10. McDevitt DG, Shanks RG, Swanton JG. Further observations on the cardiotoxicity of isoprenaline during hypoxia. Br J Pharmacol 1974;50:335-44.
  11. Burggraaf J, Westendorp RG, in't Veen JC, Schoemaker RC, Sterk PJ, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001;56:567-9.
  12. Bahnmiller N. Planning ahead: albuterol and the potential for hypokalemia-induced ventricular tachycardia in prehospital care. JEMS 2006;31:30.
  13. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006;117:18-24; quiz 25.
  14. Wechsler ME. Managing asthma in the 21st century: role of pharmacogenetics. Pediatr Ann 2006;35:660-2, 664-9.
  15. Williams C. Cause of death in the SMART Trial. Chest 2006;130:929-30; author reply 930.
  16. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF Jr, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285:2583-93.
  17. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010;65:39-43.
  18. Walters JA, Wood-Baker R, Walters EH. Long-acting beta2-agonists in asthma: an overview of Cochrane systematic reviews. Respir Med 2005;99:384-95.
  19. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev: CD006922;2009.
  20. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists—the influence of values. N Engl J Med 2009;360:1592-5.
  21. Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev: CD007694;2010.
  22. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-7.
  23. Knobil K. Long-acting beta-agonists in asthma. N Engl J Med 2009;361:208-9; author reply 209.
  24. Lundborg M, Wille S, Bjermer L, Tilling B, Lundgren M, et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Curr Med Res Opin 2006;22:809-21.
  25. Agarwal R, Khan A, Aggarwal AN, Gupta D. Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta-analysis. Monaldi Arch Chest Dis 2009;71:161-9.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.